Bryan Johnson Edits His Genes To Live Past 120 

Tech mogul Bryan Johnson undergoes follistatin gene therapy to explore its potential for extending human lifespan beyond 120 years.


Aging &amp; Longevity

Musk is suing OpenAI for not sharing and profiting from its latest technology. 


(Image modified from New York Times) OpenAI CEO Sam Altman (left) and OpenAI co-founder Elon Musk (right). 

Elon Musk sues OpenAI over money grabs and keeping its technology from the public. 

Others

Biohackers Convene in Honduras for Unregulated Gene Therapy Trials

Under purported “innovation-friendly” regulation in Próspera, Honduras, the biohacking company Minicircle is conducting trials testing whether their gene therapy technique bolsters muscle building and longevity.

(The city of Próspera on the Honduran island of Roatán | prospera.co)

A startup biohacking company called Minicircle has begun testing gene therapies in far-off Honduras with goals of developing more affordable pro-longevity therapies without FDA oversight.

Backed by the largest-ever individual investment towards a longevity startup from OpenAI CEO Sam Altman, Retro Biosciences will begin to tackle aging via cellular reprogramming, autophagy, and plasma-inspired therapeutics.   

Investor and OpenAI CEO Sam Altman | MIT Technology Review  

Search Result: OpenAI

Bryan Johnson Edits His Genes To Live Past 120

Elon Musk’s Lawsuit Pressures OpenAI to Release ChatGPT’s Secret Technology

Biohackers Convene in Honduras for Unregulated Gene Therapy Trials Without FDA Oversight

ChatGPT Founder Sam Altman’s New Startup Retro Biosciences Aims to Reverse Aging